Walder Wyss advised the investors co-led by Kurma Partners and Sunstone Life Science Venture on the deal, while VISCHER advised Synendos. Synendos Therapeutics (Synendos), a biopharmaceutical…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
